Meine Merkliste  

3.517 Aktuelle Fachpublikationen von Future Medicine


Sie können Ihre Recherche weiter verfeinern. Wählen Sie aus dem linken Bereich passende Suchfilter aus, um Ihre Ergebnisse gezielt einzugrenzen.

Identifying genetic loci affecting antidepressant drug response in depression using drug–gene interaction models

01.06.2016 | Raymond Noordam; Christy L Avery; Loes E Visser; Bruno H Stricker, Pharmacogenomics, 2016

Antidepressants are often only moderately successful in decreasing the severity of depressive symptoms. In part, antidepressant treatment response in patients with depression is genetically determined. However, although a large number of studies have been conducted aiming to identify genetic ...


One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity

01.06.2016 | Daniel L Hertz; James M Rae, Pharmacogenomics, 2016

Pharmacogenomics Ahead of Print.


Pharmacogenetics of ribavirin-induced anemia in HCV patients

01.06.2016 | Antonio D'Avolio; Jessica Cusato; Amedeo De Nicolò; Sarah Allegra; Giovanni Di Perri, Pharmacogenomics, 2016

Dual therapy (pegylated interferon plus ribavirin) was considered the standard of care for hepatitis C virus (HCV) treatment until 2011, when the first-wave direct-acting antivirals were added to this regimen for HCV genotype-1 patients to increase the sustained virological response rate. The ...


Considerations of pharmacogenetic testing in children

01.06.2016 | Susanne B Haga; Benjamin D Solomon, Pharmacogenomics, 2016

Pharmacogenomics Ahead of Print.


Cost–effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines

01.06.2016 | Lucía Cortejoso; Xandra García-González; María I García; Pilar García-Alfonso; María Sanjurjo; Luis A López-Fernández, Pharmacogenomics, 2016

Aim: To compare the cost of screening for three mutations in the dihydropyrimidine dehydrogenase gene and the costs of treating severe fluoropyrimidine-induced neutropenia. Materials & methods: The polymorphisms rs3918290 (DPYD*2A), rs67376798 (DPYD 2846A>T) and rs55886062 (1679T>G, DPYD*13) were ...


Evidence for extensive pleiotropy among pharmacogenes

01.06.2016 | Matthew T Oetjens; William S Bush; Joshua C Denny; Kelly Birdwell; Nuri Kodaman; Anurag Verma; Holli H Dilks; Sarah ..., Pharmacogenomics, 2016

Aim: We sought to identify potential pleiotropy involving pharmacogenes. Methods: We tested 184 functional variants in 34 pharmacogenes for associations using a custom grouping of International Classification and Disease, Ninth Revision billing codes extracted from deidentified electronic health ...


Requirements for comprehensive pharmacogenetic genotyping platforms

01.06.2016 | Volker M Lauschke; Magnus Ingelman-Sundberg, Pharmacogenomics, 2016

Recent research highlighted the large extent of rare variants in pharmacogenes and, on this basis, it was estimated that rare variants account for 30–40% of the functional variability in pharmacogenes. It has been proposed that comprehensive next-generation sequencing (NGS)-based sequencing of ...


Evaluation of methodology for the analysis of ‘time-to-event’ data in pharmacogenomic genome-wide association studies

01.06.2016 | Hamzah Syed; Andrea L Jorgensen; Andrew P Morris, Pharmacogenomics, 2016

Aim: To evaluate the power to detect associations between single nucleotide polymorphisms and time-to-event outcomes across a range of pharmacogenomic study designs while comparing alternative regression approaches. Materials & methods: Simulations were conducted to compare Cox proportional ...


Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus

01.06.2016 | Jazlina Liza Jamaluddin; Hasniza Zaman Huri; Shireene Ratna Vethakkan, Pharmacogenomics, 2016

Aim: To determine the clinical and genetic predictors of the dipeptidyl peptidase-4 (DPP-4) inhibitor treatment response in Type 2 diabetes mellitus (T2DM) patients. Patients & methods: DPP4, WFS1 and KCNJ11 gene polymorphisms were genotyped in a cohort study of 662 T2DM patients treated with ...


SSRs as genetic markers in the human genome and their observable relationship to hereditary diseases

27.05.2016 | Tun-Wen Pai; Chien-Ming Chen, Biomarkers in Medicine, 2016

Biomarkers in Medicine Ahead of Print.


Seite 3 von 352
Suche per e-Mail abonnieren

Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.